Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
KROS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.78 - $72.37
Previous CloseN/A
Volume109.28K
Average Volume (3M)919.29K
Market Cap
$455.11M
Enterprise Value$1.67B
Total Cash (Recent Filing)$559.93M
Total Debt (Recent Filing)$18.86M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
May 01, 2025EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.01
Shares Outstanding40,562,046
10 Day Avg. Volume664,198
30 Day Avg. Volume919,291
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)128.20
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap3.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit470.85
Enterprise Value/Ebitda-8.98
Forecast
1Y Price Target
$28.50Price Target Upside154.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Keros Therapeutics News
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Major Conferences
PremiumCompany Announcements
Keros Therapeutics Strengthens Financial Position Amid R&D Expansion
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Biotech Conference
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe partnership with Takeda for elritercept includes a $200M upfront payment and future royalties, providing a financial runway into 4Q28.
Market PotentialThe opportunity for ‘065 could be sizeable, with potential applications for a range of neuromuscular disorders and neurodegenerative diseases.
Safety ProfileA comparison with sotatercept suggests a significantly larger safety margin of cibotercept, likely due to more selective ligand binding.
Bears Say
Clinical TrialsThe Phase 2 TROPOS study for cibotercept was terminated early due to unanticipated pericardial effusion events and a risk/benefit assessment.
Market CatalystsWithout the PAH program, which was a major focus for investors, there are limited near-term catalysts from the partnered elritercept program.
ValuationKeros Therapeutics, Inc. is being downgraded from OUTPERFORM to NEUTRAL after removing cibotercept for PAH and KER-065 for obesity from their valuation.
---
Ownership Overview
8.42% Insiders
22.73% Mutual Funds
39.47% Other Institutional Investors
19.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $9.78 and its highest was $72.37 in the past 12 months.
What is Keros Therapeutics’s market cap?
Keros Therapeutics’s market cap is $455.11M.
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Feb 26, 2025. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.356 by $0.216.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -1.2.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 40,562,046 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.356. Following the earnings report the stock price went up 0.64%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Currently, no hedge funds are holding shares in KROS
---
Keros Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.50 (154.01% Upside)
$28.50 (154.01% Upside)
Blogger Sentiment
Neutral
KROS Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 384.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.74%
12-Months-Change
Fundamentals
Return on Equity
-41.46%
Trailing 12-Months
Asset Growth
66.44%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
---
KROS Stock 12 Month Forecast
Average Price Target
$28.50
▲(154.01% Upside)
Technical Analysis
Fate Therapeutics
―
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Blueprint Medicines
―
Argenx Se
―
Best Analysts Covering KROS
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+3.12%
reiterated a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +3.12% per trade.
---